MAPT and Parkinson disease: Collectively, nilotinib effects on neurodegenerative pathology, including PD, may be mediated by multiple changes, representing a “biomarker mix” that includes reduction of CSF oligomeric α‐synuclein and p‐tau, which affect the brain motor and nonmotor systems, and improvement of dopamine metabolism.17, 18, 19, 20, 22